PRESS RELEASE

from MEDIAN TECHNOLOGIES (EPA:ALMDT)

Changes in the rights attaching to the classes of shares or securities

image 

Press release – For immediate release May 10, 2024 – 5:45 pm CEST

Disclosure of total number of voting rights and number of shares in the capital as of April 30th, 2024

 

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

 

Sophia Antipolis, France 

 

Total number of shares

18,418,233

Number of real voting rights*                   (excluding treasury shares**)

18,346,685

Theoretical number of voting rights*            (including treasury shares**)

18,298,337

(*) Class E preference shares are non-voting 

(**) pursuant to article 223-11 of the AMF’s General Regulations

 

 

imageAbout Median Technologies: Pioneering in innovative imaging solutions and services,

image

Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer diagnoses and cancer treatments. Median's offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. The French-based company, with a presence in the U.S. and China, is listed on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: www.mediantechnologies.com   

Contacts

 

Median Technologies

Emmanuelle Leygues

Head of Corporate Marketing & Financial

Communications

+33 6 10 93 58 88                   

emmanuelle.leygues@mediantechnologies.com  

Press - ALIZE RP

Caroline Carmagnol  +33 6 64 18 99 59 median@alizerp.com    

Investors - ACTIFIN

Ghislaine Gasparetto +33 6 21 10 49 24

ghislaine.gasparetto@seitosei-actifin.com 

 

 

1 | P a g e

See all MEDIAN TECHNOLOGIES news